Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ETC-1002 Clear all
Completed Phase 2 Interventional

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

NCT01941836
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
68
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

NCT02993406
View directory record Official record
Conditions
Cardiovascular Diseases, Statin Adverse Reaction
Interventions
Bempedoic acid 180 mg tablet, Matching placebo tablet
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
13,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
304
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

NCT01262638
View directory record Official record
Conditions
Dyslipidemia
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Chandler, Arizona • Greenbrae, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

NCT01607294
View directory record Official record
Conditions
Hyperlipidemia, Type 2 Diabetes
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

NCT01779453
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

NCT03193047
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
bempedoic acid 180mg, placebo, evolocumab
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

NCT01485146
View directory record Official record
Conditions
Safety Evaluation of Escalating Doses
Interventions
ETC-1002
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

NCT03067441
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598
View directory record Official record
Conditions
Mild Dyslipidemia
Interventions
ETC-1002 or placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

NCT02178098
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

NCT03001076
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
Interventions
Bempedoic acid, Ezetimibe, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

NCT03051100
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

NCT02991118
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid, placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Clearwater, Florida • Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

NCT02072161
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Statin Therapy
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Muscle Shoals, Alabama • Chandler, Arizona • Chino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

NCT03337308
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
Combination Product · Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

NCT01751984
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 4, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 4, 2026, 12:23 PM EDT